Evaluation of the Safety and Efficacy of Reformulated Raltegravir (MK-0518) 1200 mg Once Daily in Combination With TRUVADA™ in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-Naive Participants (MK-0518-292)

NCT02131233 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

802

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infection

Interventions

DRUG: Reformulated Raltegravir
DRUG: Raltegravir
DRUG: TRUVADA™
DRUG: Placebo to Reformulated Raltegravir
DRUG: Placebo to Raltegravir

Sponsor

Merck Sharp & Dohme LLC